Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market By Drug Type (Biologics, Immunosuppressants); By Treatment Approach (First-Line Therapies, Second-Line Therapies); By Route of Administration (Intravenous, Subcutaneous); By Region, Segment Revenue Estimation, Forecast, 2026–2032

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market: FcRn Adoption Reshapes an Immunoglobulin-Dominated Category

The Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market is estimated to reach USD 2.21 billion in 2025 and is projected to grow to USD 3.13 billion by 2032, expanding at a CAGR of 5.1% during the forecast period, according to Strategic Market Research.

 

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market is defined by a small diagnosed population requiring prolonged and often expensive immunomodulatory therapy. Commercial demand is concentrated in maintenance treatment, where repeated intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), corticosteroids, and newer targeted biologics are used to prevent relapse and preserve mobility.

 

The 2021 EAN/PNS guideline recommends IVIg or corticosteroids as initial treatment for typical CIDP and most variants. Plasma exchange is recommended when these options are ineffective, while IVIg, SCIg, or corticosteroids may be used for maintenance. These recommendations continue to protect the position of plasma-derived immunoglobulin, but the approval of efgartigimod introduced a targeted alternative for patients who previously had few options outside immunoglobulin, steroids, and plasma exchange.

 

Market expansion will depend less on rapid epidemiological growth than on four changes in treatment practice: identifying patients whose disease is inadequately controlled, converting suitable patients from infusion-based therapy to targeted or home-administered options, improving diagnosis, and demonstrating that higher-priced therapies reduce relapse, disability, and treatment burden sufficiently to support reimbursement.

 

Claims-Based Epidemiology Produces a Much Larger Commercial Population

Published epidemiological estimates differ sharply according to how CIDP cases are identified. A global meta-analysis estimated pooled incidence at 0.33 cases per 100,000 person-years and prevalence at 2.81 cases per 100,000 people. National studies have also produced substantial variation, including prevalence of approximately 7.0 per 100,000 in the Netherlands and 1.16 per 100,000 in South Korea. Differences in diagnostic criteria, population age, access to neurology services, and case-confirmation methods limit direct comparison between countries. 

A U.S. claims analysis published in 2026 estimated that, in 2023, CIDP incidence reached 2.8 per 100,000 people and prevalence reached 23.3 per 100,000. This corresponded to approximately 9,238 incident patients and 77,058 prevalent patients. Rates were higher among older adults and particularly among men aged 55 years or above. The authors cautioned that diagnostic misclassification in claims data could inflate these estimates.

Commercial market models should therefore distinguish between the broad coded or claims-identified population and the narrower clinically confirmed treatment-eligible population. Applying the U.S. claims rate directly to other countries would overstate the opportunity. Conversely, relying only on clinically adjudicated prevalence may understate diagnosed patients already receiving treatment through routine healthcare systems.

The gap between the two populations also affects forecasting by therapy class. Claims-based estimates are useful for assessing reimbursement exposure and existing prescription activity, while specialist-confirmed cohorts are more appropriate for estimating adoption of therapies requiring documented active disease, prior treatment failure, or detailed neurological assessment.

 

Maintenance Treatment Generates Most Recurring Demand

The chronic and relapsing course of CIDP makes maintenance treatment the principal source of recurring revenue. In the 2023 U.S. claims study, 66.7% of estimated incident patients and 53.9% of prevalent patients received a CIDP treatment during the year. Among treated patients, corticosteroids were used by 75.2% of incident and 69.9% of prevalent patients. Immunoglobulin was used by 57.8% and 51.9%, respectively, with IVIg accounting for nearly all immunoglobulin use. SCIg penetration remained low at 1.7% of treated incident patients and 3.6% of treated prevalent patients.

A five-country European survey covering 542 patients found that 85.4% were receiving maintenance therapy. Among the 463 patients on treatment, 47.1% received IVIg, 8.0% SCIg, 40.6% oral corticosteroids, 6.5% intravenous corticosteroids, and 11.2% biologic therapy. Approximately 63.3% were receiving first-line treatment, 30.2% second-line treatment, and 6.5% third-line-or-later therapy.

Treatment intensity increased with disability. Current or previous rescue-treatment use rose from 24.6% among patients with mild disability to 31.7% among those with moderate disability and 43.6% among those with severe disease. IVIg and high-dose corticosteroids were the most commonly reported rescue treatments. This pattern makes relapse prevention commercially important beyond drug acquisition costs because worsening disease increases hospital use, caregiver requirements, mobility-aid use, and productivity losses.

The most valuable patient group is consequently not determined only by diagnosis. Commercial value is concentrated among patients who have active disease, require repeated maintenance treatment, relapse after dose reduction, or cannot tolerate long-term corticosteroids.

 

Immunoglobulin Retains the Largest Treatment Position

IVIg remains deeply embedded in CIDP care because it has established efficacy, extensive physician familiarity, and a rapid clinical effect in many patients. Its use spans induction, maintenance, and rescue treatment, giving immunoglobulin suppliers access to several stages of the treatment pathway.

The market is also evolving within the immunoglobulin category. Takeda received U.S. approval for Gammagard Liquid in January 2024 for induction and maintenance treatment in adults with CIDP. In the same month, HyQvia received U.S. approval as maintenance therapy to prevent relapse. HyQvia combines immunoglobulin with recombinant hyaluronidase and can be administered every two, three, or four weeks by a healthcare professional or self-administered after appropriate training.

CSL Behring’s Hizentra provides an established weekly SCIg option. In the PATH study, 81% of patients receiving 0.4 g/kg weekly and 67% receiving 0.2 g/kg remained relapse-free for up to 24 weeks, compared with 44% of patients receiving placebo. The higher-dose regimen produced stronger relapse protection but also requires greater weekly immunoglobulin volume, creating a trade-off between disease control, administration frequency, and treatment burden.

SCIg products compete less by replacing immunoglobulin as a class than by shifting administration away from infusion centres. Home treatment can reduce travel, chair time, and dependence on infusion capacity, although patients must accept more frequent administration, local-site reactions, or large subcutaneous volumes. HyQvia’s less frequent dosing creates a different value proposition from weekly Hizentra, while conventional IVIg remains suitable for patients who prefer supervised treatment or require high induction doses.

Immunoglobulin manufacturers can therefore defend their CIDP franchises through dosing flexibility, home-administration support, nursing networks, and differentiated IVIg and SCIg portfolios. Novel biologics must compete against this established infrastructure rather than against a single reference product.

 

Vyvgart Hytrulo Establishes the Targeted Biologic Segment

The FDA approval of argenx’s Vyvgart Hytrulo in June 2024 created the first targeted FcRn treatment category in adult CIDP. The subcutaneous therapy reduces circulating IgG by inhibiting the neonatal Fc receptor and offers a mechanistically targeted alternative to replacement immunoglobulin and broad immunosuppression.

In the ADHERE study, 66.5% of the 322 participants achieved confirmed clinical improvement during the initial treatment stage. Among responders who entered randomized withdrawal, efgartigimod reduced the risk of relapse by 61% compared with placebo, with a hazard ratio of 0.39. The trial included treatment-naïve patients and patients previously receiving immunoglobulin or corticosteroids, although previously treated participants had to discontinue therapy and demonstrate active worsening before starting efgartigimod.

This design established treatment efficacy but left an important commercial implementation question: how stable IVIg patients should be transitioned without exposing them to avoidable deterioration. The issue affects physician confidence, patient selection, and payer policies because routine practice does not normally require a patient to worsen deliberately before accessing another treatment.

Early switch evidence has been encouraging but remains limited. A Phase IV open-label study enrolled 23 patients receiving stable IVIg and initiated efgartigimod one week after their last IVIg dose. Twenty patients completed the 12-week period, while two experienced CIDP worsening shortly after transition and recovered after resuming prior therapy. Broader expert-reported experience presented in an industry-supported symposium described successful switching in most patients, but the evidence was non-randomized and should not be interpreted as comparative superiority over IVIg.

Separate case reports have documented early deterioration after transition from IVIg to FcRn therapy. These reports do not invalidate efgartigimod’s controlled-trial results, but they reinforce the need for individualised timing, baseline functional measurement, and rapid access to rescue therapy during conversion.

Argenx’s first-mover advantage is strongest among patients with active disease, substantial infusion burden, steroid intolerance, or inadequate control on existing therapy. Penetration among stable IVIg patients will depend on real-world relapse rates, transition protocols, prescriber familiarity, prior-authorization requirements, and the comparative annual cost of weekly efgartigimod versus immunoglobulin.

European Commission approval in June 2025 expanded the commercial opportunity across all 27 EU member states, Iceland, Liechtenstein, and Norway. Actual uptake will remain country-specific because national health technology assessment, pricing negotiation, and reimbursement decisions determine how quickly regulatory approval becomes funded access.

 

The Pipeline Is Concentrated in FcRn and Complement-Directed Therapies

Although broader drug-development databases identify approximately 25 CIDP pipeline programs, only a limited number have reached commercially meaningful late-stage development. Competition is concentrated in FcRn inhibition and selective complement blockade, reflecting efforts to move beyond repeated immunoglobulin administration and broad immunosuppression.

Argenx is evaluating empasiprubart, a complement C2 inhibitor, in the Phase III EMVIGORATE and EMNERGIZE programs. EMVIGORATE is strategically important because it compares empasiprubart directly with IVIg, while EMNERGIZE uses a placebo-controlled design. Positive head-to-head evidence against IVIg would carry greater commercial weight than another withdrawal study because it could support direct treatment substitution. Argenx also has an established CIDP commercial infrastructure through Vyvgart Hytrulo, which could allow the company to position FcRn and complement therapies for different patient groups. Top-line results from these Phase III programs are expected in the second half of 2027.

Dianthus Therapeutics is advancing claseprubart, previously known as DNTH103, in the Phase III CAPTIVATE trial. The drug inhibits active C1s within the classical complement pathway and is being developed as a subcutaneous treatment administered once every two weeks. The study reached its predefined interim threshold after 20 confirmed responders were identified during the open-label enrichment stage. This decision supported continuation into the controlled portion of the trial, but it should not be interpreted as evidence of superiority over placebo or IVIg. Commercial differentiation will depend on relapse prevention, infection risk, dosing convenience, and whether efficacy is maintained across clinically diverse CIDP populations.

Sanofi’s riliprubart program experienced a major setback in June 2026 when the company discontinued the Phase III MOBILIZE study. An independent monitoring committee concluded that the trial was unlikely to demonstrate sufficient efficacy in patients whose disease was refractory to standard treatment. Sanofi stated that the decision was not associated with a new safety signal. The company was still assessing the future of the VITALIZE study in patients receiving IVIg. The MOBILIZE outcome reduces confidence in complement inhibition among highly refractory patients, but it does not invalidate the broader therapeutic approach because riliprubart, claseprubart, and empasiprubart differ in molecular design, target position, study population, and trial structure.

Immunovant’s batoclimab program provided clinical evidence supporting FcRn inhibition but is not currently positioned as a registrational CIDP asset. In a Phase IIb study involving 73 pooled participants, batoclimab produced a 1.8-point improvement in adjusted INCAT score at Week 12. The company also reported an 84% response rate among patients who achieved IgG reductions of at least 70%. Immunovant subsequently stated that it did not intend to seek CIDP approval for batoclimab and would instead use the findings to guide the development of IMVT-1402, its next-generation FcRn inhibitor. IMVT-1402 may therefore become the company’s principal commercial candidate in CIDP if future studies confirm efficacy with a more favourable dosing, safety, or pharmacodynamic profile.

The late-stage pipeline remains narrower than the headline count of approximately 25 programs suggests. Argenx currently has the strongest competitive position because it combines an approved FcRn therapy with a Phase III complement program. Dianthus represents the nearest independent complement competitor, while Immunovant is attempting to translate batoclimab’s proof-of-concept findings into a potentially registrational IMVT-1402 program. Sanofi’s riliprubart setback increases scrutiny of complement-targeted development and raises the importance of patient selection, biomarker strategy, responder definitions, and trial design.

 

Diagnostic Accuracy Limits the Real Treatment-Eligible Population

CIDP diagnosis remains a material market-sizing constraint because no single biomarker confirms the disease. Referral-centre studies have found that 32% of patients in one European cohort and 47% in one U.S. tertiary-centre cohort carrying a previous CIDP diagnosis did not meet the investigators’ required diagnostic standards. These figures come from selected referral populations and should not be extrapolated to all diagnosed patients, but they demonstrate how misinterpretation of electrophysiology, mild protein elevation, subjective treatment response, and diagnostic coding can inflate the apparent market.

The U.S. claims analysis also showed limited specialist involvement. Only 53.2% of incident and 30.1% of prevalent patients had a neurologist visit during the assessed period. Neurologists were more likely to prescribe immunoglobulin, while non-neurologists relied more heavily on corticosteroids. Specialist access therefore affects both diagnosis and the therapy mix.

New therapies may increase the commercial value of confirming diagnosis because payers are likely to require documented clinical deterioration, electrophysiological support, objective response, or prior treatment history before authorising high-cost biologics. Better diagnostic enforcement could reduce inappropriate immunoglobulin use while concentrating spending among patients most likely to benefit.

 

Treatment Withdrawal Creates Both Savings Pressure and Relapse Risk

Not every stable patient requires indefinite full-dose maintenance therapy. In a randomized IVIg-withdrawal study, 41% of patients assigned to withdrawal remained stable for 24 weeks, compared with 58% continuing IVIg. Approximately 28% of the withdrawal group remained stable through the extension period. Among patients who relapsed after withdrawal, 94% restabilized within 12 weeks after IVIg was restarted.

These findings support supervised withdrawal or dose-reduction attempts in selected stable patients. They also create a commercial headwind for models that assume uninterrupted lifetime treatment for every diagnosed patient. Payers and specialist centres may increasingly use objective functional measures to identify overtreated patients, adjust immunoglobulin doses, or confirm treatment dependence before approving a novel therapy.

For manufacturers, durable revenue will depend on demonstrating active disease and measurable maintenance benefit rather than relying solely on historical diagnosis. Products that enable predictable dose optimisation or identify likely responders could gain an advantage as reimbursement becomes more evidence-based.

 

Disability Prevention Strengthens the Value Case for Effective Maintenance

Treatment cost accounts for a large proportion of CIDP expenditure, but drug-cost comparisons alone understate the financial effect of uncontrolled disease. A U.S. case-control study of 790 CIDP patients and 790 matched controls reported mean two-year healthcare costs of USD 116,330 per CIDP patient, compared with USD 15,586 among controls. CIDP therapy represented 51.2% of total costs. Hospitalisation occurred in 26.2% of CIDP patients versus 9.0% of controls, while emergency-room use reached 42.2% versus 21.9%. The study used 2010–2014 claims and should be viewed as a structural burden benchmark rather than a current pricing estimate.

The recent five-country European survey found that informal caregiver support was required by 7.2% of mildly disabled patients, 31.2% of moderately disabled patients, and 62.9% of severely disabled patients. Work-productivity loss among employed patients increased from 21.8% in mild disease to 44.0% in moderate disease and 67.3% in severe disease. Hospitalisation, emergency admission, mobility-aid use, and home modifications also increased with disability.

These data give manufacturers an opportunity to frame treatment value around preserved function, avoided relapse, lower rescue-treatment use, and reduced caregiver dependence. Payers will still require evidence that clinical-trial improvements translate into lower resource use, particularly when a novel therapy is used in patients who were already stable on immunoglobulin.

 

Segment Implications

Immunoglobulins will retain the largest therapy share: IVIg remains established across induction, maintenance, and rescue care. SCIg growth will come primarily from conversion of existing immunoglobulin patients rather than newly diagnosed patients entering treatment directly through the subcutaneous route.

Targeted biologics represent the most strategically important expansion segment: Efgartigimod has established the category, while complement inhibitors and next-generation FcRn agents could broaden it. Adoption will be determined by response durability, transition safety, dosing convenience, and payer willingness to fund treatment before multiple standard therapies have failed.

Subcutaneous administration will gain share, but products will remain differentiated by frequency and burden: Weekly injections, weekly SCIg infusions, and facilitated SCIg every two to four weeks are not interchangeable experiences. Volume, administration time, training, local reactions, home-support services, and rescue protocols will influence patient persistence.

Maintenance patients will account for most revenue: Incident treatment begins the clinical pathway, but repeated maintenance dosing generates the larger cumulative opportunity. IVIg-dependent patients, patients experiencing end-of-dose deterioration, and patients with steroid toxicity are particularly relevant conversion populations.

Hospital neurology and specialist clinics will remain central to initiation: Home infusion and self-administration can shift subsequent doses away from hospitals, but diagnosis, treatment selection, functional assessment, and management of early deterioration require specialist involvement.

 

Regional Market Position

North America represents the most commercially developed CIDP treatment market because of its large claims-identified population, extensive immunoglobulin utilisation, established home-infusion networks, and early access to targeted biologics. The same market faces substantial utilisation management because claims-based prevalence, diagnostic uncertainty, and high annual treatment costs expose payers to overtreatment risk.

Europe is a major adoption region but remains fragmented by national reimbursement. Efgartigimod’s EU approval provides broad regulatory coverage, while the use of IVIg, oral corticosteroids, and SCIg varies by country and clinical setting. Health technology assessment will place greater emphasis on comparative value, quality of life, site-of-care savings, and whether new therapy reduces immunoglobulin consumption.

Asia-Pacific contains large populations but a less consistently diagnosed CIDP pool. South Korea’s nationwide prevalence of 1.16 per 100,000 is substantially below the recent U.S. claims estimate. Japan and China have become important markets for targeted neuromuscular therapies, but access across the wider region remains constrained by specialist availability, reimbursement, electrophysiological testing capacity, and immunoglobulin supply.

No robust public epidemiological dataset is available for North Korea. Extrapolating South Korean prevalence to North Korea would be unreliable because healthcare access, diagnostic infrastructure, and reporting systems differ substantially. North Korea should therefore not be included as a separately quantified CIDP treatment opportunity without primary evidence.

 

Competitive Outlook

The CIDP treatment market is shifting from broad immunomodulation toward a mixed model in which immunoglobulin, targeted IgG reduction, and complement inhibition coexist. Immunoglobulin suppliers retain advantages in clinical familiarity, guideline positioning, product variety, and established distribution. Argenx holds the first targeted-biologic position and can build around an existing prescriber base, real-world evidence program, and international approvals.

The next competitive reset will depend on the Phase III outcomes for empasiprubart and claseprubart. A successful head-to-head comparison against IVIg would carry greater commercial weight than another placebo-controlled withdrawal study because it could influence direct treatment substitution. Conversely, additional complement-program failures would strengthen FcRn positioning and preserve immunoglobulin use among patients who require rapid, established disease control.

Commercial growth will come primarily from better patient identification and therapy conversion rather than a sudden increase in disease prevalence. Manufacturers will need to show which patients should switch, when the transition should occur, how deterioration will be managed, and whether the new regimen reduces total treatment burden. Companies that combine efficacy with practical dosing, specialist support, objective monitoring, and credible payer evidence will capture the highest-value maintenance population.

 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.21 Billion
Revenue Forecast in 2032	USD 3.13 Billion
Overall Growth Rate	CAGR of 5.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Drug Type	Biologics; Immunosuppressants
By Treatment Approach	First-Line Therapies; Second-Line Therapies
By Route of Administration	Intravenous; Subcutaneous
By Region	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Customization Option	Available upon request